Results 1 to 10 of about 47,993 (230)

Oculomotor nerve palsy in neurofibromatosis type 2 [PDF]

open access: yesRadiology Case Reports, 2022
Neurofibromatosis (NF) type 2 is a rare neurological, autosomal dominant and genetic disorder. It is caused by a mutation in the tumor suppressor gene, called NF2 gene. The disorder results in several benign tumors of the nervous system.
Aymen Shahab, MBBS   +6 more
doaj   +2 more sources

Psychiatric symptoms in neurofibromatosis type 2 [PDF]

open access: yesEuropean Psychiatry, 2021
Introduction Neurofibromatosis type 2 (NF2) is a rare disorder associated with significant morbidity such as hearing loss that can lead to many psychiatric disorders. Objectives Describe the psychiatric symptoms associated to NF2. Methods We report
S. Khouadja   +3 more
doaj   +2 more sources

Central nervous system manifestations of neurofibromatosis type 2: A case report [PDF]

open access: yesRadiology Case Reports, 2023
Neurofibromatosis type 2 (phacomatosis) is a rare inherited autosomal dominant condition defined by the development of numerous central neuronal tumors.
Zineb Izi, MD   +5 more
doaj   +2 more sources

The genetic landscape and possible therapeutics of neurofibromatosis type 2 [PDF]

open access: yesCancer Cell International, 2023
Neurofibromatosis type 2 (NF2) is a genetic condition marked by the development of multiple benign tumors in the nervous system. The most common tumors associated with NF2 are bilateral vestibular schwannoma, meningioma, and ependymoma.
Mohammad Amin Ghalavand   +5 more
doaj   +2 more sources

Optic nerve and choroidal calcification in pediatric neurofibromatosis type 2 [PDF]

open access: yesAmerican Journal of Ophthalmology Case Reports
We describe a teenage boy with gradually progressive blurred vision in right eye. He could appreciate hand motions in the right eye and 20/20 vision in the left eye. Ophthalmic examination revealed bilateral optic atrophy with yellow-white peri-papillary
Shreya Gupta   +3 more
doaj   +2 more sources

Characteristics of MicroRNA Expression Depending on the Presence or Absence of Meningioma in Patients with Neurofibromatosis Type 2: A Secondary Analysis [PDF]

open access: yesNeurologia Medico-Chirurgica
Meningioma is the second most frequent tumor in patients with neurofibromatosis type 2 (NF2). The presence of meningioma is believed to be a negative prognostic marker in these patients.
Takeshi IMURA   +2 more
doaj   +2 more sources

Neurofibromatosis type 2

open access: yesJournal of Child Neurology, 2016
Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder (incidence 1:33 000-40 000) characterized by formation of central nervous system tumors, due to mutation in the NF2 gene on chromosome 22q12. Vestibular schwannomas are the hallmark lesion, affecting 95% of individuals and typically occur bilaterally.
Simone Ardern-Holmes   +2 more
  +8 more sources

Neurofibromatosis type 2 [PDF]

open access: yesThe Lancet, 2009
Neurofibromatosis type 2 is an autosomal-dominant multiple neoplasia syndrome that results from mutations in the NF2 tumour suppressor gene located on chromosome 22q. It has a frequency of one in 25,000 livebirths and nearly 100% penetrance by 60 years of age.
Ashok R, Asthagiri   +6 more
  +6 more sources

Ophthalmic Manifestation in Neurofibromatosis Type 2

open access: yesApplied Sciences, 2023
Neurofibromatosis type 2 (NF2) is a genetically determined tumor-predisposing syndrome. Ocular manifestations include cataracts, epiretinal membranes, retinal hamartomas, optic disk gliomas, and optic nerve sheath meningiomas. Moreover, optic disk edema,
Marta Armentano   +10 more
doaj   +1 more source

Neurofibromatosis type 2 [PDF]

open access: yesNeurology, 2007
A 45-year-old woman developed a gradual onset of sensorineural hearing loss in the left ear in 1984. Head CT scan with contrast demonstrated bilateral cerebellopontine angle (CPA) enhancing masses. She underwent a resection of the left CPA tumor with pathology confirming schwannoma. …
S, Sathornsumetee   +4 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy